167 related articles for article (PubMed ID: 18755985)
1. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.
Wang PY; Young F; Chen CY; Stevens BM; Neering SJ; Rossi RM; Bushnell T; Kuzin I; Heinrich D; Bottaro A; Jordan CT
Blood; 2008 Nov; 112(10):4184-92. PubMed ID: 18755985
[TBL] [Abstract][Full Text] [Related]
2. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
Chang KH; Sanchez-Aguilera A; Shen S; Sengupta A; Madhu MN; Ficker AM; Dunn SK; Kuenzi AM; Arnett JL; Santho RA; Agirre X; Perentesis JP; Deininger MW; Zheng Y; Bustelo XR; Williams DA; Cancelas JA
Blood; 2012 Jul; 120(4):800-11. PubMed ID: 22692505
[TBL] [Abstract][Full Text] [Related]
3. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
4. Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of
van Oosterwijk JG; Li C; Yang X; Opferman JT; Sherr CJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7420-7425. PubMed ID: 28652370
[TBL] [Abstract][Full Text] [Related]
5. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
[TBL] [Abstract][Full Text] [Related]
6. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
7. The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia.
Ma H; Mallampati S; Lu Y; Sun B; Wang E; Leng X; Gong Y; Shen H; Yin CC; Jones D; Amin HM; You MJ; Zweidler-McKay P; Ma Y; Kantarjian HM; Arlinghaus RB; Glassman A; Sun X
Haematologica; 2014 Oct; 99(10):1591-8. PubMed ID: 24997151
[TBL] [Abstract][Full Text] [Related]
8. Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.
Zimmerman RS; Rosenberg N
J Virol; 2008 Sep; 82(17):8383-91. PubMed ID: 18579612
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.
Williams RT; den Besten W; Sherr CJ
Genes Dev; 2007 Sep; 21(18):2283-7. PubMed ID: 17761812
[TBL] [Abstract][Full Text] [Related]
10. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
11. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
12. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
13. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
[TBL] [Abstract][Full Text] [Related]
14. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
15. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
[TBL] [Abstract][Full Text] [Related]
16. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
Heisterkamp N; Voncken JW; Senadheera D; Gonzalez-Gomez I; Reichert A; Haataja L; Reinikainen A; Pattengale PK; Groffen J
Blood; 2000 Sep; 96(6):2226-32. PubMed ID: 10979970
[TBL] [Abstract][Full Text] [Related]
17. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
18. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
19. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation.
Radfar A; Unnikrishnan I; Lee HW; DePinho RA; Rosenberg N
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13194-9. PubMed ID: 9789064
[TBL] [Abstract][Full Text] [Related]
20. Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Gillis LC; Berry DM; Minden MD; McGlade CJ; Barber DL
Leukemia; 2013 Aug; 27(8):1666-76. PubMed ID: 23399893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
